• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一类具有中性P1侧链的肽硼酸酯作为凝血酶高度选择性抑制剂的特性研究。

Characterization of a class of peptide boronates with neutral P1 side chains as highly selective inhibitors of thrombin.

作者信息

Deadman J J, Elgendy S, Goodwin C A, Green D, Baban J A, Patel G, Skordalakes E, Chino N, Claeson G, Kakkar V V

机构信息

Thrombosis Research Institute, London, United Kingdom.

出版信息

J Med Chem. 1995 Apr 28;38(9):1511-22. doi: 10.1021/jm00009a012.

DOI:10.1021/jm00009a012
PMID:7739010
Abstract

Z-D-Phe-Pro-boroMpg-OPin (9a)1,2 has been shown previously to be a highly specific inhibitor of thrombin in spite of lacking an arginine-like guanidino group at the P1 site. A range of compounds have been synthesized based upon this lead compound, varying the neutral side chain at the P1 site. Of the 20 examples based upon the structures at P2 and P3 of Z-D-X-Pro (X being Phe or beta,beta-diphenylalanine), all were found to be effective inhibitors of thrombin (Ki's between 10 and 100 nM). Furthermore all exhibited a high specificity toward thrombin having values for a Ki(trypsin)/Ki(thrombin) ratio of between 10- and 100-fold. High ratio values were found for a number of the compounds tested against a range of serine proteinases (plasmin, factor Xa, kallikrein, urokinase, protein Ca, chymotrypsin, elastase, and cathepsin G). As far as potency toward thrombin, compounds containing the methoxypropyl group at P1 were favored over those with a methoxy grouping on a shorter alkyl chain (8) or without the methoxy group (1-5). The compounds display potent anticoagulant activity with values for 18 in thrombin time of 0.63 microM and in activated partial thromboplastin time of 2.0 microM. 11B NMR has been used to confirm interaction of the boron atom with the active site. From the high specificity shown with all the compounds we propose that the compounds, constitute a new class of thrombin inhibitors.

摘要

Z-D-苯丙氨酸-脯氨酸-硼甲基苯丙氨酸-OPin(9a)1,2先前已被证明是一种高度特异性的凝血酶抑制剂,尽管其P1位点缺乏类似精氨酸的胍基。基于该先导化合物合成了一系列化合物,改变了P1位点的中性侧链。在基于Z-D-X-脯氨酸(X为苯丙氨酸或β,β-二苯基丙氨酸)的P2和P3结构的20个实例中,所有化合物均被发现是有效的凝血酶抑制剂(Ki值在10至100 nM之间)。此外,所有化合物对凝血酶均表现出高特异性,Ki(胰蛋白酶)/Ki(凝血酶)比值在10至100倍之间。在针对一系列丝氨酸蛋白酶(纤溶酶、因子Xa、激肽释放酶、尿激酶、蛋白C、胰凝乳蛋白酶、弹性蛋白酶和组织蛋白酶G)测试的许多化合物中发现了高比值。就对凝血酶的效力而言,P1位点含有甲氧基丙基的化合物优于那些在较短烷基链上带有甲氧基的化合物(8)或没有甲氧基的化合物(1-5)。这些化合物显示出强大的抗凝活性,凝血酶时间为0.63 microM,活化部分凝血活酶时间为2.0 microM。11B NMR已用于确认硼原子与活性位点的相互作用。从所有化合物显示的高特异性来看,我们提出这些化合物构成了一类新的凝血酶抑制剂。

相似文献

1
Characterization of a class of peptide boronates with neutral P1 side chains as highly selective inhibitors of thrombin.一类具有中性P1侧链的肽硼酸酯作为凝血酶高度选择性抑制剂的特性研究。
J Med Chem. 1995 Apr 28;38(9):1511-22. doi: 10.1021/jm00009a012.
2
Structure/function aspects of neutral P1 residue peptide inhibitors of thrombin.
J Enzyme Inhib. 1995;9(1):29-41. doi: 10.3109/14756369509040679.
3
In vitro and in vivo characterization of a neutral boron-containing thrombin inhibitor.一种含硼中性凝血酶抑制剂的体外和体内特性研究
J Biol Chem. 1993 Mar 5;268(7):4734-41.
4
The selective inhibition of thrombin by peptides of boroarginine.硼精氨酸肽对凝血酶的选择性抑制作用。
J Biol Chem. 1990 Oct 25;265(30):18289-97.
5
Selection of S18326 as a new potent and selective boronic acid direct thrombin inhibitor.选择S18326作为一种新型强效且选择性的硼酸直接凝血酶抑制剂。
Thromb Haemost. 1997 Oct;78(4):1221-7.
6
New inhibitors of thrombin and other trypsin-like proteases: hydrogen bonding of an aromatic cyano group with a backbone amide of the P1 binding site replaces binding of a basic side chain.凝血酶及其他类胰蛋白酶的新型抑制剂:芳香族氰基与P1结合位点主链酰胺之间的氢键作用取代了碱性侧链的结合。
Biochemistry. 1997 Oct 28;36(43):13180-6. doi: 10.1021/bi970912m.
7
In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications to structure-based drug design.基于三肽的α-酮杂环作为凝血酶抑制剂的深入研究。S1'亚位点的有效利用及其对基于结构的药物设计的意义。
J Med Chem. 2005 Mar 24;48(6):1984-2008. doi: 10.1021/jm0303857.
8
Bifunctional peptide boronate inhibitors of thrombin: crystallographic analysis of inhibition enhanced by linkage to an exosite 1 binding peptide.凝血酶的双功能肽硼酸酯抑制剂:通过与外位点1结合肽连接增强抑制作用的晶体学分析
Biochemistry. 1998 Oct 13;37(41):14420-7. doi: 10.1021/bi980225a.
9
Benzyloxycarbonyl-D-Phe-Pro-methoxypropylboroglycine: a novel inhibitor of thrombin with high selectivity containing a neutral side chain at the P1 position.苄氧羰基-D-苯丙氨酸-脯氨酸-甲氧基丙基硼甘氨酸:一种新型的凝血酶抑制剂,在P1位含有中性侧链,具有高选择性。
Biochem J. 1993 Mar 1;290 ( Pt 2)(Pt 2):309-12. doi: 10.1042/bj2900309.
10
Structure-activity study of tripeptide thrombin inhibitors using alpha-alkyl amino acids and other conformationally constrained amino acid substitutions.
J Med Chem. 1995 Oct 27;38(22):4446-53. doi: 10.1021/jm00022a009.

引用本文的文献

1
Preclinical investigation of patient-derived cervical cancer organoids for precision medicine.患者来源宫颈癌类器官的精准医学前临床研究。
J Gynecol Oncol. 2023 May;34(3):e35. doi: 10.3802/jgo.2023.34.e35. Epub 2022 Dec 30.
2
Boroleucine-Derived Covalent Inhibitors of the ZIKV Protease.基于硼酸亮氨酸的 Zika 病毒蛋白酶共价抑制剂。
ChemMedChem. 2023 Feb 1;18(3):e202200336. doi: 10.1002/cmdc.202200336. Epub 2022 Nov 21.
3
Covalent Antiviral Agents.共价抗病毒药物。
Adv Exp Med Biol. 2021;1322:285-312. doi: 10.1007/978-981-16-0267-2_11.
4
An efficient methodology to introduce -(aminomethyl)phenyl-boronic acids into peptides: alkylation of secondary amines.一种将-(氨甲基)苯基硼酸引入肽中的有效方法:仲胺的烷基化反应。
New J Chem. 2017 Jan 7;41(1):126-133. doi: 10.1039/C6NJ02862D. Epub 2016 Nov 17.
5
Functionality map analysis of the active site cleft of human thrombin.人凝血酶活性位点裂隙的功能图谱分析
J Comput Aided Mol Des. 1996 Feb;10(1):1-10. doi: 10.1007/BF00124460.